Published in Cardiovascular Business Week, August 19th, 2008
Abiomed's Impella 2.5 capacity expansion plans in Ireland are intended to meet anticipated long-term demand for the device and augment capacity from the Company's Aachen, Germany facility. In June 2008, Abiomed announced that it had received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Impella 2.5 that...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.